|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Breast self examinationThe American Cancer Society (ACS) recommends that:
Benefits:
A major problem with breast self-examination as a screening technique is that it is rarely performed well. Clinical breast examinationThe ACS recommends clinical breast examination for women:
The clinical examination should include inspection and palpation of the breast and regional lymph nodes. If the clinician detects an abnormality, the patient should then undergo diagnostic imaging rather than screening. Benefits:
MammographyScreening mammography is performed in the asymptomatic patient to detect an occult breast cancer. Currently, the American Cancer Society recommends:
Benefits:
This, however, does not apply to younger women, particularly those aged younger than 40 years. In addition, the sensitivity of mammography is decreased significantly in young patients with dense breast tissue and possibly with augmentation prosthesis. Mammography seldom is recommended in patients younger than 30 years. Exceptions to this rule would be young women with extensive family histories for breast cancer.
Mammographic findings & suggestive lesions
BI-RADSThe American College of Radiology established the standard for
classification of radiographic abnormalities, known as the Breast
Imaging Reporting and Data System
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BI-RAD Class | Description | Recommendation |
| 0 | Incomplete examination | Usually requiring further imaging or evaluation |
| I | Normal | Follow-up study in 1 year |
| II | Benign | Follow-up study in 1 year |
| III | Likely to be benign | Follow-up mammogram in 6 months |
| IV | Suspicious | Consider biopsy |
| V | Highly suspicious for malignancy | Biopsy recommended |
As an adjunct to mammography, ultrasonography (US) can be particularly useful in younger patients or women with fibrocystic change and should be the initial investigation for palpable lesions in women younger than 35 years. Its main use remains in distinguishing solid from cystic lesions. In the workup of nonpalpable lesions, US can be used to guide a needle biopsy or to place a localizing wire to direct an excisional biopsy.
In palpable masses it sensitivity and specificity are about 95%.
MRI is a particularly useful modality for detailing architectural abnormalities in the breast and can help detect lesions as small as 2-3 mm. MRI should be used in scarred breasts, implants, multifocal lesions, and for borderline lesions planned for breast conservation.
Has a sensitivity approaching 100% but its specificity is only 50%.
The label typically used is technetium Tc 99m Sestamibi, a compound that concentrates in mitochondria and whose efflux is related to expression of the multidrug resistance protein. Therefore, the size of the signal distinguishes the high metabolic rate of a malignant tumor and may help predict resistance to chemotherapy.
Scintimammography is less sensitive than MRI for lesions smaller than 1 cm, is more specific for palpable lesions and is useful for detecting axillary involvement. It can also be useful in cases with impalpable masses due to its high specificity in this setting.
Has a sensitivity and specificity of 90% in detection of impalpable masses.
PET is the most sensitive and specific of all the imaging modalities for breast disease. However, it is also one of the most expensive and least widely available. PET is useful in axillary assessment, scarred breasts, and multifocal lesions.
Has a sensitivity of 95% and specificity of 100%.
|
|
|
|
|
|
|